ArticleFrontiers in immunology2025
Coexistence of anti-neurexin-3α-associated autoimmune encephalitis and systemic lupus erythematosus in an adult patient: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune encephalitis (AE) associated with anti-neurexin-3α antibodies, an uncommon variant of AE, exhibits particularly low frequency when coexisting with systemic immune dysregulation. The heterogeneous clinical manifestations of this neuroinflammatory disorder hinder timely diagnosis. We describe a 55-year-old male diagnosed with anti-neurexin-3α-associated AE, complicated by systemic lupus erythematosus (SLE) and antiphospholipid antibodies. The case presented with pyrexia persisting for 3 days, followed by acute-onset vertigo and encephalopathy evolving over 7 h. The clinical course was marked by visual obscuration, cephalalgia with associated emetic episodes, and concurrent neuropsychiatric manifestations, including psychomotor agitation and urinary incontinence. Anti-neurexin-3α antibody was detected in the cerebrospinal fluid. The patient tested positive for anti-neutrophil cytoplasmic antibody, anti-SS-A/RO60KD, anti-SS-A/RO52, anti-SnRNP, and lupus anticoagulant. Plasma complement levels (C3 and C4) were decreased, while elevated titers were observed for antinuclear antibodies, anti-double-stranded DNA, and anti-β2 glycoprotein I IgG antibodies. Immunomodulatory therapy with pulse methylprednisolone and intravenous immunoglobulin infusion elicited marked neurological recovery. This case underscores the imperative to investigate AE in the differential diagnosis of acute neuropsychiatric decompensation, and it is important to consider changes related to the aforementioned pathologies during physical examination and imaging evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.